![]() Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan. Yanada M, Takami A, Mizuno S, Mori J, Chou T, Usuki K, et al. Role of hematopoietic stem cell transplantation in acute promyelocytic leukemia. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Sanz MA, Fenaux P, Tallman MS, Estey EH, Lowenberg B, Naoe T, et al. Our findings demonstrate very favorable long-term results when autologous HCT is conducted during CR2 + across the various subgroups of patients with relapsed APL. The other factors such as age, disease status, and MRD status were not predictive for the survival outcomes. The multivariate analysis revealed that the duration of first CR ( < or ≥2 years) was the sole factor associated with RFS ( P = 0.002), but even those with CR1 duration <2 years showed a 5-year RFS of 76%. The 5-year probabilities of relapse-free survival (RFS), overall survival, relapse, and nonrelapse mortality for the entire cohort were 85%, 88%, 9%, and 6%, respectively. Of the 286 patients whose measurable residual disease (MRD) data were available, 21 showed detectable MRD. Among them, 24 patients were ≥65 years old, and 17 underwent autologous HCT during third or subsequent CR. To address this question, we analyzed 296 patients with APL who had undergone autologous HCT during second or subsequent complete remission (CR2+) between 20. However, it remains unclear whether this procedure is equally effective for certain groups of patients. Autologous hematopoietic cell transplantation (HCT) is an effective therapy for patients with relapsed acute promyelocytic leukemia (APL).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |